Rita Jain (AVTX) Reports 1,572 Stock Options, Fully Vested

Rhea-AI Filing Summary

Rita Jain, a director of Avalo Therapeutics, Inc. (AVTX), reported a grant of stock options on 09/30/2025. The filing shows the grant of 1,572 stock options with an exercise price of $12.71. The options were reported as 100% vested in the explanatory note. The options are linked to 1,572 underlying shares and are held directly by Ms. Jain following the transaction. The derivative table lists an expiration or related date of 09/30/2035, and the reported transaction was signed by a power of attorney on 10/02/2025.

Positive

• Options are 100% vested, indicating immediate exercisability as reported
• Grant size is modest at 1,572 options, limiting immediate dilution

Negative

• None.

Insights

Corporate Governance Analyst

Director received fully vested options for 1,572 shares at $12.71.

The Form 4 discloses a grant of 1,572 stock options to Rita Jain on 09/30/2025 with an exercise price of $12.71. The filing explicitly states the options are 100% vested and that the options relate to 1,572 underlying shares held directly.

The table shows an associated date of 09/30/2035 in the derivative section, which is presented as the listed expiration/related date. The filing was executed by power of attorney on 10/02/2025, confirming timely reporting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jain Rita

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,572	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,572 shares (Direct)

Footnotes (1)

1. F1. The options were granted on September 30, 2025, and are 100% vested.

FAQ

What did Rita Jain report on Form 4 for AVTX?

She reported a grant of 1,572 stock options on 09/30/2025 with an exercise price of $12.71.

Are the options vested according to the filing?

Yes. The filing states the options were granted on 09/30/2025 and are 100% vested.

How many shares does the option cover and who owns them?

The options cover 1,572 underlying shares and are reported as directly owned following the transaction.

What is the exercise price and listed expiration date for the options?

The exercise price is $12.71 and the derivative table lists 09/30/2035 as the related expiration/dated entry.

When was the Form 4 signed and filed?

The signature (by power of attorney) is dated 10/02/2025 and the transaction date reported is 09/30/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/02/2025 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Jain Rita

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.71	09/30/2025		A		1,572		(1)	09/30/2035	Common Stock	1,572	$0	1,572	D

Explanation of Responses:

1. The options were granted on September 30, 2025, and are 100% vested.

	/s/ Donald R. Reynolds, by Power of Attorney	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.